1-19 of 19
Subject: Prostate
Journal Article
Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics
The Oncologist, Volume 26, Issue 4, April 2021, Pages e715–e718, https://doi.org/10.1002/onco.13694
Published: 09 February 2021
Journal Article
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
The Oncologist, Volume 26, Issue 2, February 2021, Pages e270–e278, https://doi.org/10.1002/onco.13601
Published: 03 December 2020
Journal Article
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer
The Oncologist, Volume 26, Issue 2, February 2021, Pages 139–146, https://doi.org/10.1002/onco.13585
Published: 17 November 2020
Journal Article
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA
The Oncologist, Volume 26, Issue 1, January 2021, Pages e115–e129, https://doi.org/10.1634/theoncologist.2020-0697
Published: 08 September 2020
Journal Article
AR‐V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost‐Saving Analysis
The Oncologist, Volume 25, Issue 12, December 2020, Pages e1990–e1995, https://doi.org/10.1634/theoncologist.2020-0043
Published: 19 August 2020
Journal Article
Long‐Term Disease Control Using Taxane/Platinum‐Based Chemotherapy in CDK12‐Mutated Advanced Prostate Cancer
The Oncologist, Volume 25, Issue 9, September 2020, Pages e1421–e1422, https://doi.org/10.1634/theoncologist.2020-0260
Published: 12 July 2020
Journal Article
Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration‐Sensitive Prostate Cancer
The Oncologist, Volume 25, Issue 7, July 2020, Pages e1042–e1050, https://doi.org/10.1634/theoncologist.2019-0495
Published: 19 March 2020
Journal Article
Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 (177Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer
The Oncologist, Volume 25, Issue 6, June 2020, Pages 477–e895, https://doi.org/10.1634/theoncologist.2020-0028
Published: 30 January 2020
Journal Article
Axicabtagene Ciloleucel, an Anti‐CD19 Chimeric Antigen Receptor T‐Cell Therapy for Relapsed or Refractory Large B‐Cell Lymphoma: Practical Implications for the Community Oncologist
The Oncologist, Volume 25, Issue 1, January 2020, Pages e138–e146, https://doi.org/10.1634/theoncologist.2019-0395
Published: 04 October 2019
Journal Article
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
The Oncologist, Volume 24, Issue 9, September 2019, Pages 1149–e807, https://doi.org/10.1634/theoncologist.2019-0331
Published: 31 May 2019
Journal Article
A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
The Oncologist, Volume 24, Issue 4, April 2019, Pages 430–432, https://doi.org/10.1634/theoncologist.2018-0819
Published: 09 January 2019
Journal Article
Biomarkers for Programmed Death‐1 Inhibition in Prostate Cancer
The Oncologist, Volume 24, Issue 4, April 2019, Pages 444–448, https://doi.org/10.1634/theoncologist.2018-0546
Published: 12 December 2018
Journal Article
Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial
The Oncologist, Volume 23, Issue 12, December 2018, Pages 1413–e151, https://doi.org/10.1634/theoncologist.2018-0652
Published: 01 November 2018
Journal Article
Laboratory‐Based Biomarkers and Liver Metastases in Metastatic Castration‐Resistant Prostate Cancer
The Oncologist, Volume 23, Issue 7, July 2018, Pages 791–797, https://doi.org/10.1634/theoncologist.2017-0564
Published: 26 April 2018
Journal Article
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
The Oncologist, Volume 23, Issue 6, June 2018, Pages 656–e64, https://doi.org/10.1634/theoncologist.2017-0624
Published: 27 February 2018
Journal Article
Extreme Prostate‐Specific Antigen Response to Infusional 5‐Flourouracil in Castrate‐Resistant Prostate Cancer
The Oncologist, Volume 23, Issue 3, March 2018, Pages 383–385, https://doi.org/10.1634/theoncologist.2017-0450
Published: 19 December 2017
Journal Article
Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
The Oncologist, Volume 23, Issue 2, February 2018, Pages 193–202, https://doi.org/10.1634/theoncologist.2017-0413
Published: 28 November 2017
Journal Article
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
The Oncologist, Volume 22, Issue 5, May 2017, Pages 503–e43, https://doi.org/10.1634/theoncologist.2016-0432
Published: 17 March 2017
Journal Article
End‐of‐Life Care Matters: Palliative Cancer Care Results in Better Care and Lower Costs
The Oncologist, Volume 22, Issue 4, April 2017, Pages 361–368, https://doi.org/10.1634/theoncologist.2016-0277
Published: 17 March 2017
